Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 6;4(5):e389. doi: 10.1038/tp.2014.26

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

PMC Copyright notice

The mean BDNF and trkB−TK+ mRNA levels of individuals on antidepressants (a, b) or mood stabilizers (c) at the time of death compared with patients free of antidepressants or mood stabilizers at the time of death and to unaffected controls. (a) BDNF levels were significantly reduced in DLPFC layers II (P=0.006) and V (P=0.01) in patients not taking any antidepressants at the time of death as compared with the controls. (b) TrkB−TK+ levels were significantly reduced in OFC layers IV (P=0.008) and VI (P=0.001) in patients not taking any antidepressants at the time of death as compared with controls. (c) TrkB−TK+ mRNA levels were significantly reduced in OFC layer IV (P=0.01), in ACC layers III (P=0.02), Va (P=0.002) and Vb (P=0.01) and in ITG layers II (P=0.0006), III (P=0.004), IV (P=0.015) and V (P=0.01) in the patient group not taking any mood stabilizers at the time of death as compared with the controls groups.